These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32676325)

  • 1. Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma.
    Gu W; Wang N; Gu W; Qiu Y; Zhang H; Liang J; Zhou T; Ma L; Cai W; Feng W; Chen L
    Transl Lung Cancer Res; 2020 Jun; 9(3):629-638. PubMed ID: 32676325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.
    Jiao XD; Zhang XC; Qin BD; Liu D; Liu L; Ni JJ; Ning ZY; Chen LX; Zhu LJ; Qin SB; Ying SP; Chen XQ; Li AJ; Hou T; Han-Zhang H; Ye J; Zheng J; Chuai S; Zang YS
    Ann Transl Med; 2020 Jul; 8(14):860. PubMed ID: 32793704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of tumor mutation burden in
    Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS
    J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The co-mutation of
    Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
    J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas.
    Wang C; Liang H; Lin C; Li F; Xie G; Qiao S; Shi X; Deng J; Zhao X; Wu K; Zhang X
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
    Zhuang W; Ma J; Chen X; Wang G; Lu J; Chen Y; Dong H; Cai S; Zhang Y; Zhao X; Zhu Y; Xu C; Huang Y; Huang Z; Zhu X; Jiang H; Wang Z
    J Cancer; 2018; 9(13):2302-2307. PubMed ID: 30026825
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
    Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
    Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational status of main driver genes influences the prognosis of stage I-III lung adenocarcinoma patients underwent radical surgery.
    Liao H; Luo X; Liang Y; Wan R; Xu M
    Transl Cancer Res; 2021 Jul; 10(7):3286-3298. PubMed ID: 35116635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer.
    Wang J; Chen P; Su M; Zhong G; Zhang S; Gou D
    Biomed Res Int; 2022; 2022():2698190. PubMed ID: 35097114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma.
    Chen X; Ou Z; Wang L; Zhang Z; Fan X; Liu H; Wang W; Zhang Y; Zhu J; Liang X; Lou F; Cao S; Yao Y; Wang H; Yao X
    Mol Carcinog; 2022 Mar; 61(3):311-321. PubMed ID: 34729830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiomics analysis of tumor mutational burden across cancer types.
    Li L; Bai L; Lin H; Dong L; Zhang R; Cheng X; Liu Z; Ouyang Y; Ding K
    Comput Struct Biotechnol J; 2021; 19():5637-5646. PubMed ID: 34745455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
    Lv J; Zhu Y; Ji A; Zhang Q; Liao G
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden.
    Chiu TY; Lin RW; Huang CJ; Yeh DW; Wang YC
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34198473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.
    Li L; Chen C; Liu C; Niu L; Pan C
    Ann Transl Med; 2022 Feb; 10(4):214. PubMed ID: 35280376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.